Melioidosis News and Research

RSS
CDC and Task Force for Global Health to co-host 11th International Conference on Emerging Infectious Diseases

CDC and Task Force for Global Health to co-host 11th International Conference on Emerging Infectious Diseases

CDC identifies bacteria that cause rare melioidosis in domestic environmental samples

CDC identifies bacteria that cause rare melioidosis in domestic environmental samples

Researchers discover new family of sensing genes in enteric bacteria using AI

Researchers discover new family of sensing genes in enteric bacteria using AI

INRS professor developing a glycoconjugate vaccine for melioidosis

INRS professor developing a glycoconjugate vaccine for melioidosis

Poolbeg and University College Dublin sign an Option Agreement to license melioidosis vaccine candidate

Poolbeg and University College Dublin sign an Option Agreement to license melioidosis vaccine candidate

CDC: Cause of melioidosis outbreak confirmed

CDC: Cause of melioidosis outbreak confirmed

CDC lab testing identifies deadly bacteria in an aromatherapy spray

CDC lab testing identifies deadly bacteria in an aromatherapy spray

VALIDATE Network’s TB vaccine work receives $1.5 million funding boost

VALIDATE Network’s TB vaccine work receives $1.5 million funding boost

Researchers develop mathematical model for monitoring, controlling spread of melioidosis

Researchers develop mathematical model for monitoring, controlling spread of melioidosis

Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

Deadly bacteria can travel to the brain and spinal cord in 24 hours, new study finds

Deadly bacteria can travel to the brain and spinal cord in 24 hours, new study finds

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Emergent BioSolutions sign development agreement

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix closes previously announced registered public offering

Soligenix closes previously announced registered public offering